What is the reduction in cardiovascular risk attributed to statin therapy?

Statin therapy has been shown to significantly reduce cardiovascular events in individuals with a history of cardiovascular disease and in those at high risk due to other factors such as diabetes, hypertension, and hyperlipidemia. The reduction in cardiovascular risk attributed to statin therapy typically ranges from 20% to 30%. This reduction is supported by strong evidence from multiple large-scale clinical trials, which demonstrated that statins not only lower LDL cholesterol levels but also have beneficial effects on inflammation and endothelial function, contributing to overall cardiovascular risk reduction.

As a result, patients on statin therapy have a lower incidence of major adverse cardiovascular events, including myocardial infarction and stroke. This consistent finding across various populations underscores the importance of statins in preventive cardiology, solidifying the estimate of a 20-30% risk reduction as an established guideline in clinical practice.